May 7, 2019 / 6:05 PM / 12 days ago

BRIEF-Novartis Says New AveXis Data At AAN Showed Long-Term Durability Of Zolgensma In Patients With SMA Type 1

May 7 (Reuters) - Novartis AG:

* NEW AVEXIS DATA AT AAN SHOWED LONG-TERM DURABILITY OF ZOLGENSMA® IN PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) TYPE 1

* NOVARTIS - AS OF MARCH 8, 2019, ALL PATIENTS MAINTAINED MOTOR FUNCTION AND MILESTONES GAINED DURING TRIAL FOLLOWING TREATMENT WITH ZOLGENSMA

* NO NEW TREATMENT-RELATED ADVERSE EVENTS HAVE EMERGED DURING FOLLOW-UP PERIOD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below